Wealth Ltd News Today

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Wednesday. Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, April 9th. Check Out Our Latest […]

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a report published on Tuesday. Separately, HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, April 9th. Get Our Latest Stock Analysis […]

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a report released on Tuesday morning. Separately, HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Galectin Therapeutics in a report on Tuesday, April 9th. View Our Latest Report on […]

Solutions 4 Wealth Ltd bought a new stake in Tesla, Inc. (NASDAQ:TSLA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,005 shares of the electric vehicle producer’s stock, valued at approximately $498,000. Tesla comprises about 1.6% of Solutions […]

Solutions 4 Wealth Ltd acquired a new stake in Vanguard Health Care ETF (NYSEARCA:VHT – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,225 shares of the company’s stock, valued at approximately $1,310,000. Vanguard Health Care ETF accounts for 4.3% […]

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns […]

StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a research report report published on Monday. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Monday. Read Our Latest Research Report […]

JS Global Capital has been appointed the authorised participant and market maker of the ETF.

Advice firms that do not have a client portal are less valuable to potential buyers than those that do. That was the view of those taking part in a panel discussion on the subject at the Empowering Advice Through Technology (EATT) conference in London today. Research conducted in advance of the conference revealed

Aberdeen chartered financial planning trainee Kelly Shek, of AAB Wealth, says they need to be a good listener for starters.